Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SASHA COURTNEY DAVIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1194019075
CMS profile
2378874
Location
TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$209.43

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $209.43 5

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $96.24 1
Novocure Inc. $60.43 1
Karyopharm Therapeutics Inc. $18.81 1
E.R. Squibb & Sons, L.L.C. $17.62 1
AbbVie Inc. $16.33 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SASHA COURTNEY DAVIS

NPI 1194019075 · CMS profile ID 2378874

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TYLER, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
SASHA COURTNEY DAVIS, NPI 1194019075, CMS profile ID 2378874, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1194019075?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $209.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $16.3311/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722144487 CMS
Novocure Inc. $60.4309/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740699187 CMS
E.R. Squibb & Sons, L.L.C. $17.6208/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727787363 CMS
Karyopharm Therapeutics Inc. $18.8108/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751735349 CMS
Celgene Corporation $96.2402/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727787383 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $388.85 10
PY2020 $209.43 5
PY2021 $358.15 15
PY2022 $556.52 18
PY2023 $1,071.10 29
PY2024 $1,344.13 48
PY2025 $747.53 34

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $91,150.24 16
PY2024 Principal investigator $102,318.97 23
PY2023 Principal investigator $167,396.92 32
PY2022 Principal investigator $244,503.39 39
PY2021 Principal investigator $409,588.59 46
PY2020 Principal investigator $357,909.58 144
PY2019 Principal investigator $105,582.24 109

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

144 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $1,048.00 12/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837159
Principal investigator 1 PFIZER INC. $30,804.46 12/03/2020 Non-covered Recipient Entity
USO Texas OncologyTyler
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 742901811
Principal investigator 1 Radius Health, Inc. $53,999.42 11/25/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112817
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837277
Principal investigator 1 Merck Sharp & Dohme Corporation $695.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837297
Principal investigator 1 Merck Sharp & Dohme Corporation $695.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740838071
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740838633
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 11/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740839397
Principal investigator 1 Merck Sharp & Dohme Corporation $1,895.50 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836769
Principal investigator 1 Merck Sharp & Dohme Corporation $1,323.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836969
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837349
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837821
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740838611
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740838613
Principal investigator 1 Merck Sharp & Dohme Corporation $680.00 10/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740838671
Principal investigator 1 Radius Health, Inc. $956.00 10/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111335
Principal investigator 1 Merck Sharp & Dohme Corporation $1.80 10/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740846599
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 10/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740846601
Principal investigator 1 Merck Sharp & Dohme Corporation $24.00 10/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740846779
Principal investigator 1 Merck Sharp & Dohme Corporation $3.00 10/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740846781
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 10/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740846783
Principal investigator 1 Merck Sharp & Dohme Corporation $4.00 10/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740846785
Principal investigator 1 Merck Sharp & Dohme Corporation $1.80 10/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740847547
Principal investigator 1 Merck Sharp & Dohme Corporation $4.60 10/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740847549
Principal investigator 1 Novartis Pharmaceuticals Corporation $90.00 10/06/2020 Non-covered Recipient Entity
US ONCOLOGY P A
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ALPELISIB (BYL719) IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH ADVANCED TRIPLE NEGATIVE BREAST CANCER WITH EITHER PHOSPHOINOSITIDE-3- No dispute reported 06/30/2026 721497353
Principal investigator 1 Radius Health, Inc. $30,875.00 10/01/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112815
Principal investigator 1 PFIZER INC. $7,592.58 09/24/2020 Non-covered Recipient Entity
USO Texas OncologyTyler
POLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUDY No dispute reported 06/30/2026 742950305
Principal investigator 1 Radius Health, Inc. $1,810.00 09/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111203
Principal investigator 1 Radius Health, Inc. $1,975.00 09/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111213
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 09/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760415
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 09/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760751
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 09/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760753
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 09/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760755
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 09/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760757
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 09/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760791
Principal investigator 1 Merck Sharp & Dohme Corporation $29.70 09/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760793
Principal investigator 1 Radius Health, Inc. $565.00 09/03/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112747
Principal investigator 1 Radius Health, Inc. $565.00 09/03/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112763
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837017
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837809
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841591
Principal investigator 1 Merck Sharp & Dohme Corporation $1,655.50 08/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740842691
Principal investigator 1 Radius Health, Inc. $3,075.00 08/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111151
Principal investigator 1 Radius Health, Inc. $2,223.00 08/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111155
Principal investigator 1 Radius Health, Inc. $2,399.00 08/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111169
Principal investigator 1 Radius Health, Inc. $2,648.00 08/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111177
Principal investigator 1 Radius Health, Inc. $1,160.00 08/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111195
Principal investigator 1 Radius Health, Inc. $2,648.00 08/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111295
Principal investigator 1 Radius Health, Inc. $2,648.00 08/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111297
Principal investigator 1 Merck Sharp & Dohme Corporation $20.26 08/10/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760713
Principal investigator 1 Merck Sharp & Dohme Corporation $247.59 08/10/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760749
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837219
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837607
Principal investigator 1 Merck Sharp & Dohme Corporation $680.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740839713
Principal investigator 1 Merck Sharp & Dohme Corporation $1,895.50 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740839845
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840235
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 07/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840799
Principal investigator 1 Radius Health, Inc. $956.00 07/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111263
Principal investigator 1 Merck Sharp & Dohme Corporation $91.20 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760409
Principal investigator 1 Merck Sharp & Dohme Corporation $94.32 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760411
Principal investigator 1 Merck Sharp & Dohme Corporation $171.00 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760413
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760417
Principal investigator 1 Merck Sharp & Dohme Corporation $1.92 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760707
Principal investigator 1 Merck Sharp & Dohme Corporation $14.40 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760709
Principal investigator 1 Merck Sharp & Dohme Corporation $176.85 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760711
Principal investigator 1 Merck Sharp & Dohme Corporation $45.75 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760795
Principal investigator 1 Merck Sharp & Dohme Corporation $6.10 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760797
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760799
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760831
Principal investigator 1 Merck Sharp & Dohme Corporation $7.04 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740761041
Principal investigator 1 Merck Sharp & Dohme Corporation $8.80 07/09/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740761043
Principal investigator 1 Radius Health, Inc. $24,125.00 07/09/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112751
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740833771
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740834539
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740834955
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740835273
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740835667
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740835849
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740835899
Principal investigator 1 Merck Sharp & Dohme Corporation $460.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836233
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836431
Principal investigator 1 Merck Sharp & Dohme Corporation $80.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836647
Principal investigator 1 Merck Sharp & Dohme Corporation $80.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836649
Principal investigator 1 Merck Sharp & Dohme Corporation $1,655.50 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836661
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740839763
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740839765
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740839767
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840029
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841113
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841219
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841597
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 06/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740842281
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 06/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740761035
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 06/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740761037
Principal investigator 1 Merck Sharp & Dohme Corporation $31.50 06/08/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740761039
Principal investigator 1 Radius Health, Inc. $8,000.00 05/21/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112701
Principal investigator 1 Radius Health, Inc. $16,000.00 05/21/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112705
Principal investigator 1 Radius Health, Inc. $240.00 05/21/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112709
Principal investigator 1 Radius Health, Inc. $8,000.00 05/21/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112761
Principal investigator 1 Merck Sharp & Dohme Corporation $1,895.50 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740834755
Principal investigator 1 Merck Sharp & Dohme Corporation $1,655.50 05/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840331
Principal investigator 1 Radius Health, Inc. $16,000.00 05/11/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112699
Principal investigator 1 Radius Health, Inc. $14,361.07 04/27/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112695
Principal investigator 1 Radius Health, Inc. $2,225.00 04/23/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A RANDOMIZED, MULTICENTER, PHASE 2 STUDY OF ELACESTRANT (RAD1901) VERSUS INVESTIGATORS CHOICE OF FULVESTRANT OR AROMATASE INHIBITOR THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER+/HER2- BREAST CANCER No dispute reported 06/30/2026 745112691
Principal investigator 1 Merck Sharp & Dohme Corporation $680.00 04/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841421
Principal investigator 1 Radius Health, Inc. $6,800.00 04/15/2020 Non-covered Recipient Entity
Texas Oncology, P.A.
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer No dispute reported 06/30/2026 745111355
Principal investigator 1 Radius Health, Inc. $8,000.00 03/16/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Randomized, Multicenter, Phase 2 Study Of Elacestrant (rad1901) Versus Investigators Choice Of Fulvestrant Or Aromatase Inhibitor Therapy For The Treatment Of Postmenopausal Women With Er+/her2- Breast Cancer No dispute reported 06/30/2026 745112635
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740834339
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740835135
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740835847
Principal investigator 1 Merck Sharp & Dohme Corporation $80.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740835893
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836243
Principal investigator 1 Merck Sharp & Dohme Corporation $1,895.50 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740837731
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740839825
Principal investigator 1 Merck Sharp & Dohme Corporation $1,655.50 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740839899
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840163
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840165
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840197
Principal investigator 1 Merck Sharp & Dohme Corporation $60.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840399
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840467
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840575
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840639
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740840833
Principal investigator 1 Merck Sharp & Dohme Corporation $36.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841043
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841095
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841221
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841239
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841311
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841691
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841693
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841861
Principal investigator 1 Merck Sharp & Dohme Corporation $264.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841863
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841987
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740842045
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740842159
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740842297
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740842349
Principal investigator 1 Merck Sharp & Dohme Corporation $35.00 03/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740842455
Principal investigator 1 Radius Health, Inc. $60,000.00 03/12/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Randomized, Multicenter, Phase 2 Study Of Elacestrant (rad1901) Versus Investigators Choice Of Fulvestrant Or Aromatase Inhibitor Therapy For The Treatment Of Postmenopausal Women With Er+/her2- Breast Cancer No dispute reported 06/30/2026 745112633
Principal investigator 1 Merck Sharp & Dohme Corporation $16,239.36 03/04/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY TYLER
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740760841
Principal investigator 1 Merck Sharp & Dohme Corporation $1,895.50 02/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841443
Principal investigator 1 Merck Sharp & Dohme Corporation $680.00 01/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740835117
Principal investigator 1 Merck Sharp & Dohme Corporation $582.00 01/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740836051
Principal investigator 1 Merck Sharp & Dohme Corporation $1,280.00 01/15/2020 Non-covered Recipient Entity
TEXAS ONCOLOGY, P.A.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative ER,HER2- Breast Cancer KEYNOTE-756 No dispute reported 06/30/2026 740841979